Company intelligence / Profile preview
G2GBIO
Cheongju-si (Osong-eup), Chungcheongbuk-do, South Koreag2gbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
G2GBIO has achieved preclinical drug release profiles for its target product (e.g. GB-5001) and consistent Phase 1 clinical trial results, which proved their advanced technology minimizes injection site pain and enhances bioavailability
- Therapeutic areas
- EndocrinologyPsychiatryNeurologyInfectious Diseases
- Modalities
- Small molecule drugsBiological productsSustained-release microsphere injectables
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Korea PharmaHumedix (for Alzheimer's Disease treatments)Hanwha Pharma (for hepatitis B treatments)Keyfron Bio (for veterinary medicines)
Beyond the preview
Go deeper on G2GBIO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G2GBIO.